Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/57391
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBalaz, David
dc.contributor.authorWikman-Jorgensen, Philip Erick
dc.contributor.authorGalvañ, Vicente Giner
dc.contributor.authorRubio-Rivas, Manuel
dc.contributor.authorde Miguel Campo, Borja
dc.contributor.authorLópez, Mariam Noureddine
dc.contributor.authorCaleya, Juan Francisco López
dc.contributor.authorHuelgas, Ricardo Gómez
dc.contributor.authorFontán, Paula María Pesqueira
dc.contributor.authorBailón, Manuel Méndez
dc.contributor.authorFernández-Garcés, Mar
dc.contributor.authorCruz, Ana Fernández
dc.contributor.authorGarcía, Gema María García
dc.contributor.authorRhyman, Nicolás
dc.contributor.authorCorral-Gudino, Luis
dc.contributor.authorRodríguez-Mancheño, Aquiles Lozano
dc.contributor.authorDe La Chica, María Navarro
dc.contributor.authorGarcía, Andrea Torregrosa
dc.contributor.authorAlcalá, José Nicolás
dc.contributor.authorJiménez, Pablo Díaz
dc.contributor.authorTrallero, Leticia Esther Royo
dc.contributor.authorCasanova, Pere Comas
dc.contributor.authorNúñez-Cortés, Jesús Millán
dc.contributor.authorCasas-Rojo, José-Manuel
dc.contributor.authorOn Behalf Of The Semi-Covid-Network,
dc.date.accessioned2023-01-09T14:21:41Z-
dc.date.available2023-01-09T14:21:41Z-
dc.date.issued2021-10-08
dc.identifier.citationJ Clin Med.2021;(10)19:
dc.identifier.issn2077-0383
dc.identifier.urihttps://hdl.handle.net/20.500.12530/57391-
dc.description.abstractSince the results of the RECOVERY trial, WHO recommendations about the use of corticosteroids (CTs) in COVID-19 have changed. The aim of the study is to analyse the evolutive use of CTs in Spain during the pandemic to assess the potential influence of new recommendations. A retrospective, descriptive, and observational study was conducted on adults hospitalised due to COVID-19 in Spain who were included in the SEMI-COVID-19 Registry from March to November 2020. CTs were used in 6053 (36.21%) of the included patients. The patients were older (mean (SD)) (69.6 (14.6) vs. 66.0 (16.8) years; p Patients with greater comorbidity, severity, and inflammatory markers were those treated with CTs. In severe patients, there is a trend towards the use of higher doses. The mortality benefit was observed in patients with oxygen saturation
dc.language.isoen
dc.rightsopenAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/
dc.subjectCOVID-19
dc.subjectSpain
dc.subjectcomorbidities
dc.subjectcorticosteroids
dc.titleEvolution of the Use of Corticosteroids for the Treatment of Hospitalised COVID-19 Patients in Spain between March and November 2020: SEMI-COVID National Registry.
dc.typeArtículo
dc.identifier.pubmedID34640628
dc.format.volume10
dc.identifier.journalJournal of clinical medicine
dc.identifier.journalabbreviationJ Clin Med
dc.identifier.doi10.3390/jcm10194610
dc.format.number19
dc.identifier.pmcPMC8509849
dc.pubmedtypeJournal Article
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509849/pdf
Appears in Collections:Fundaciones e Institutos de Investigación > IIS H. General U. Gregorio Marañón > Artículos
Hospitales > H. U. 12 de Octubre > Artículos
Hospitales > H. U. Infanta Cristina > Artículos

Files in This Item:
File SizeFormat 
PMC8509849.pdf996.92 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons